ReviewDrugs2011
Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Review in Drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Meta-analysis on GLP-1 mediated modulation of autophagy in islet β-cells: Prospectus for improved wound healing in type 2 diabetes.International wound journal · 2024Pooled it
- Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.Experimental diabetes research · 2012Pooled it
- Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.United European gastroenterology journal · 2026Article
- Advancements and challenges in the management of obesity using pharmacotherapy (Review).Experimental and therapeutic medicine · 2025Review
- GLP-1RAs attenuated obesity and reversed leptin resistance partlyActa pharmaceutica Sinica. B · 2025Article
- From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.Molecular biology reports · 2024Review
- Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double‑blind, randomized controlled clinical trial.Experimental and therapeutic medicine · 2023Article
- Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.Frontiers in endocrinology · 2023Review
- Amylin as a Future Obesity Treatment.Journal of obesity & metabolic syndrome · 2021Review
- Macroalgal protein hydrolysates from Palmaria palmata influence the 'incretin effect' in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion.European journal of nutrition · 2021Article
- Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice.Stem cell research & therapy · 2021Article
- Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient.Endocrinology, diabetes & metabolism case reports · 2021 · on this mapArticle
- Fluorinated phenylalanines: synthesis and pharmaceutical applications.Beilstein journal of organic chemistry · 2020Review
- Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota.Frontiers in aging neuroscience · 2020Review
- Effects of glucose-lowering agents on cardiorespiratory fitness.World journal of diabetes · 2018Review
- Autophagy and its link to type II diabetes mellitus.BioMedicine · 2017Article
- A comparative analysis of human and mouse islet G-protein coupled receptor expression.Scientific reports · 2017Article
- DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity.PloS one · 2017Article
- Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development.Journal of neuroscience methods · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 receptor agonists acting on the GLP-1 receptor, exenatide and liraglutide are available in many countries. In type 2 diabetes treatment, incretin-based therapies are attractive and more commonly used because of their mechanism of action and safety profile. Stimulation of insulin secretion and inhibition of glucagon secretion by these agents occur in a glucose-dependent manner. Therefore, incretin-based therapies have no intrinsic risk for hypoglycaemia. Furthermore, GLP-1 receptor agonists allow weight loss and lower systolic blood pressure. This review gives a brief overview of the mechanism of action and summarizes the clinical data available on exenatide and liraglutide as established substances. It further highlights the clinical study data of exenatide once weekly as the first long-acting GLP-1 receptor agonist and covers other new long acting GLP-1 receptor agonists currently in clinical development. The placement of GLP-1 receptor agonists in the treatment algorithm of type 2 diabetes is discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.